<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_FAFU-CHINA_Model_Protein_Structure skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:FAFU-CHINA/Model/Protein Structure</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="navbar navbar-inverse navbar-fixed-top"><DIV class="container"><DIV class="navbar-collapse collapse"><UL class="nav navbar-nav"><LI><A href="https://2016.igem.org/Team:FAFU-CHINA">Home</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Project </A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Description">☆Description</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Experiments">Experiments</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Notebook">Notebook</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Results">Result</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Protocol">Protocol</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Proof">☆Proof of concept</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Demonstrate">☆Demonstrate</A></LI></UL><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Part</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Parts">☆Parts</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Basic_Part">☆Basic Part</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Composite_Part">☆Composite Parts</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Modeling </A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Model/Protein_Structure">Protein Structure</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Model/Growth_Model">Growth Model</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Safety</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Safety">Safety</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/General_Lab_Safety">General Lab Safety</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Mosquitoes">Mosquitoes</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Alage">Alage</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Human Practice</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/HP/Silver">☆Silver</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/HP/Gold">☆Gold</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Integrated_Practices">☆Intergrated Practices</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Engagement">☆Engagment</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Team </A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Team">Team</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Collaborations">☆Collaborations</A></LI><LI><A href="https://2016.igem.org/Team:FAFU-CHINA/Attributions">☆Attributions</A></LI></DIV></DIV></DIV><DIV id="wrap"><DIV id="main-content" class="container"><DIV class="col-md-3" id="document-sidebar"><DIV id="toc" class="toc"><DIV id="toctitle"><H2>Contents</H2></DIV><UL><LI class="toclevel-1 tocsection-1"><A href="#Protein_Structure-_Supported_by_SCU-CHINA"><SPAN class="tocnumber">1</SPAN><SPAN class="toctext"><SPAN>Protein Structure- Supported by SCU-CHINA</SPAN></SPAN></A></LI></UL></DIV></DIV><DIV class="col-md-9" id="document-body"><P><TITLE>Team FAFU-CHINA</TITLE></P><H1><SPAN class="mw-headline" id="Protein_Structure-_Supported_by_SCU-CHINA"><SPAN style="font-family:'Times New Roman';text-align:center;text-indent:24pt">Protein Structure- Supported by SCU-CHINA</SPAN></SPAN></H1><P style="text-indent:24pt"><SPAN style="font-family:'Times New Roman';font-size:12.0000pt">In 2016 iGEM competition, FAFU-CHINA aims to use the combination of Cry and Cyt toxins to control mosquito larvae in order to decrease the disease transition like Malaria and Zika from mosquito. 2A peptides is an effective tool to co-express two different proteins with one single vector. However, when 2A peptides is cleaved during the translation, residues with a length of about 20 amino acids are remained at the end of the upstream protein and a proline remained at the beginning of the downstream protein. Because of this, we are not sure about whether the residues would affect the structure and function of the proteins that we are going to express in </SPAN><I><SPAN style="font-family:'Times New Roman';font-size:12pt">Chlamydomonas reinhardtii</SPAN></I><SPAN style="font-family:'Times New Roman';font-size:12.0000pt">, especially the Cry toxins. Therefore, SCU-CHINA team helped Tong Tong used Phyre2 to predict the secondary and tertiary structure of Cry4Aa, Cry10Aa and Cry11Aa with 2A residues. Unfortunately, the structure of Cry10Aa and Cry11Aa have not been elucidated by using X-ray crystallographic methods. Hence there is no good template in PDB database can be used and a large number of errors are reported from the results of homologous model construction for Cry10Aa-2A and Cry11Aa-2A. We were unable to estimate the effects of 2A residues to these two Cry toxins. However, the structure of Cry4Aa has been reported since 2006. We submitted the amino acid sequence of Cry4Aa-2A to Phyre2 website, using the normal mode and obtained a series of result of the homologous model. We got a reliable homologous model of Cry4Aa-2A (Fig. 1).</SPAN></P><P style="text-indent:24pt"><SPAN style="font-family:'Times New Roman';font-size:12.0000pt"> We also obtained secondary structure analysis from the result of Phyre2. Since the 2A residues structure which has a length of 39 aa is our interest, so we carefully looked into that and found about half of residues are disordered and another half are mainly </SPAN><I><SPAN style="font-family:'Times New Roman';font-size:12pt">α</SPAN></I><SPAN style="font-family:'Times New Roman';font-size:12.0000pt">-helix and a short </SPAN><I><SPAN style="font-family:'Times New Roman';font-size:12pt">β</SPAN></I><SPAN style="font-family:'Times New Roman';font-size:12.0000pt">-strand (Fig. 2).</SPAN><SPAN style="font-family:'Times New Roman';font-size:12.0000pt"> </SPAN><SPAN style="font-family:'Times New Roman';font-size:12.0000pt">Thus, we have reason to believe that the 2A residues does little impact to our Cry4Aa toxin, and it's feasible to use 2A peptides as a link between Cry and Cyt toxin for co-expression in a single vector.</SPAN></P><TABLE cellpadding="0" cellspacing="0"><TBODY><SPAN style="font-family:'Times New Roman';font-size:12.0000pt"> </SPAN><P style="text-indent:24pt"><SPAN style="font-family:'Times New Roman';font-size:12.0000pt"> </SPAN></P><P style="text-indent:24pt"><SPAN style="font-family:'Times New Roman';font-size:12.0000pt">The 2A peptides we designed for the co-expression contains 40 amino acids. After the cleavage during translation, all the amino acids except the last proline (39 aa in the red frame) are linked at the end of Cry4Aa toxin. The secondary structure analysis shows that the residues have little effect on the structure and function of the toxin.</SPAN></P><P align="right" style="text-indent:24.0000pt;text-align:right"><SPAN style="font-family:'Times New Roman';font-size:12.0000pt"> </SPAN></P><P align="right" style="text-indent:24.0000pt;text-align:right"><SPAN style="font-family:'Times New Roman';font-size:12.0000pt"> </SPAN></P><P align="right" style="text-indent:24.0000pt;text-align:right"><SPAN style="font-family:'Times New Roman';font-size:12.0000pt">Written by Zenkun Lv (SCU-CHINA) and Tong Tong (FAFU-CHINA)</SPAN></P></TBODY></TABLE></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>